Investigational drug · Phase 2
AB928
Also called: Etrumadenant, ETRUMA, GS-0928
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
22
Any phase or sponsor naming "AB928"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AB928", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
- Pancreatic Adenocarcinoma
- Metastatic Colorectal Cancer
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AB928" as an intervention, largest first.
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03193190 · 341 participants · Start Jul 5, 2017 · Primary completion Feb 27, 2025
Drug: Nab-Paclitaxel; Gemcitabine and 13 more · For: Pancreatic Adenocarcinoma
Sites: Duarte, California; San Francisco, California; New Haven, Connecticut · 23 sites in all
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.Pivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04660812 · 227 participants · Start May 10, 2021 · Primary completion Sep 5, 2025
Drug: AB680; Etrumadenant and 4 more · For: Metastatic Colorectal Cancer
Sites: Tucson, Arizona; Duarte, California; Santa Monica, California · 44 sites in all
- Study of Novel Treatment Combinations in Patients With Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05633667 · 192 participants · Start Mar 16, 2023 · Primary completion Sep 2029
Drug: Zimberelimab (ZIM); Domvanalimab (DOM) and 9 more · For: Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer
Sites: Tucson, Arizona; Fort Wayne, Indiana; Lexington, Kentucky · 89 sites in all
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04381832 · 173 participants · Start Jul 7, 2020 · Primary completion Aug 30, 2024
Drug: Etrumadenant; Zimberelimab and 4 more · For: Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistant Prostatic Neoplasms and 1 more
Sites: Cerritos, California; Encino, California; Orange, California · 19 sites in all
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04262856 · 151 participants · Start May 28, 2020 · Primary completion Jul 9, 2025
Drug: Domvanalimab; Etrumadenant and 1 more · For: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer and 1 more
Sites: Birmingham, Alabama; Whittier, California; Englewood, Florida · 44 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03555149 · 96 participants · Start Sep 27, 2018 · Primary completion Sep 26, 2022
Drug: Regorafenib; Atezolizumab and 6 more · For: Colorectal Cancer
Sites: Duarte, California; New Haven, Connecticut; Boston, Massachusetts · 15 sites in all
Arcus Biosciences, Inc.Industry
NCT03846310 · 77 participants · Start Apr 1, 2019 · Primary completion Nov 18, 2024
Drug: Etrumadenant; Zimberelimab and 3 more · For: Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer; Nonsquamous Nonsmall Cell Neoplasm of Lung and 1 more
Sites: Tucson, Arizona; Fort Myers, Florida; Tavares, Florida · 22 sites in all
David OhAcademic, hospital or other
NCT03821246 · 68 participants (planned) · Start Oct 30, 2019 · Primary completion Apr 30, 2027
Drug: Atezolizumab; Tocilizumab and 1 more · For: Prostate Adenocarcinoma; Prostate Cancer; Localized Prostate Cancer
Sites: San Francisco, California; St Louis, Missouri
Gulam ManjiAcademic, hospital or other
NCT06048484 · 60 participants (planned) · Start May 10, 2024 · Primary completion Apr 2027
Drug: Zimberelimab; Quemliclustat and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Lake Success, New York; New York, New York; Chapel Hill, North Carolina · 5 sites in all
Arcus Biosciences, Inc.Industry
NCT03629756 · 48 participants · Start Jul 24, 2018 · Primary completion Aug 18, 2021
Drug: Etrumadenant; Zimberelimab · For: Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Breast Cancer and 9 more
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Remodeling TME via feedback-driven photothermal-ferroptosis-immune cascade.
Wang S, Sun W, Yoo J, et al. · Biomaterials 2026
- Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice.
Singhal R, Zhang NW, Lee ZH, et al. · Nat Commun 2026
- The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
Cecchini M, Han SW, Lee S, et al. · Clin Cancer Res 2026
- Fatty acids in the tumor microenvironment reprogram neutrophils to induce immunosuppression via adenosine.
Singhal R, Zhang NW, Lee ZH, et al. · bioRxiv 2026
- Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines.
Cheng X, Cai H, Li X, et al. · EBioMedicine 2026
- Discovery of Novel Triple A1/A2A/A2B Adenosine Receptor Antagonists for Cancer Immunotherapy.
Jun S, Lee Y, Lee H, et al. · J Med Chem 2025
Also in development for Lung Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- zipalertinibTAS6417, CLN-081Phase 34 trials
Taiho Oncology, Inc. · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- TilesizumabBGB-108Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Lung Cancer
- HRS-4508Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Solid Tumor, Lung Cancer
- JDQ443OpnurasibPhase 23 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.